articleTop 1% cited
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2003 · Vol. 21(12) · pp. 2237–2246
Masahiro Fukuoka✉(AstraZeneca (United Kingdom))Seiji Yano(Vall d'Hebron Hospital Universitari)Giuseppe Giaccone(Life Groenkloof Hospital)Tomohide Tamura(Life Groenkloof Hospital)Kazuhiko Nakagawa(Life Groenkloof Hospital)Jean‐Yves Douillard(AstraZeneca (United Kingdom))Yutaka Nishiwaki(AstraZeneca (United Kingdom))Johan Vansteenkiste(AstraZeneca (United States))Shinzoh Kudoh(AstraZeneca (United Kingdom))Danny Rischin(AstraZeneca (United Kingdom))Richard Eek(Vall d'Hebron Hospital Universitari)Takeshi Horai(AstraZeneca (United Kingdom))Kazumasa Noda(AstraZeneca (United States))Ichiro Takata(Universitair Ziekenhuis Leuven)Egbert F. Smit(Universitair Ziekenhuis Leuven)Steven D. Averbuch(Institut Génétique Nantes Atlantique)Angela Macleod(AstraZeneca (United Kingdom))A. Feyereislova(Institut Génétique Nantes Atlantique)Rui-Ping Dong(AstraZeneca (United States))José Baselga(AstraZeneca (United States))
Abstract
Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC [corrected]
Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer ResearchGefitinibMedicineTolerabilityInternal medicineLung cancerAdverse effectChemotherapyGastroenterologyCancerEpidermal growth factor receptor
MeSH terms
GefitinibAdministration, OralAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDouble-Blind MethodEpidermal Growth FactorFemaleHumansLung NeoplasmsMaleMiddle AgedProtein-Tyrosine Kinases
Citations
2,883
FWCI
240.76
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences · 2004 · 4,332 citations
Mutations of the <b> <i>Epidermal Growth Factor Receptor</i> </b> Gene in Lung Cancer
Cancer Research · 2004 · 1,225 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Oncogene · 2009 · 979 citations
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
JNCI Journal of the National Cancer Institute · 2005 · 1,568 citations
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
BMC Cancer · 2011 · 392 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
References
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
Biometrics · 1975 · 2,349 citations
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Journal of Clinical Oncology · 2000 · 2,183 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.